FDA heart laser rejection hits PLC's figures
This article was originally published in Clinica
Executive Summary
PLC Systems saw its net loss nearly double to $9.3 million in the first half, as total revenues fell to $1.6 million from $5 million in the previous first half. The situation should improve, however, if the FDA approves its Heart Laser System for transmyocardial revascularisation (TMR) - this, the company believes, is "imminent".